|Chemical and physical data|
|Molar mass||397.409 g/mol g·mol−1|
|3D model (JSmol)|
CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects. A number of related compounds have been developed with similar properties.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|